JP2011503102A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011503102A5 JP2011503102A5 JP2010533299A JP2010533299A JP2011503102A5 JP 2011503102 A5 JP2011503102 A5 JP 2011503102A5 JP 2010533299 A JP2010533299 A JP 2010533299A JP 2010533299 A JP2010533299 A JP 2010533299A JP 2011503102 A5 JP2011503102 A5 JP 2011503102A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- seq
- reg
- microbial
- antimicrobial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 42
- 230000000845 anti-microbial effect Effects 0.000 claims 13
- 229920001184 polypeptide Polymers 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 244000000010 microbial pathogen Species 0.000 claims 11
- 208000015181 infectious disease Diseases 0.000 claims 9
- 239000000556 agonist Substances 0.000 claims 8
- 239000004599 antimicrobial Substances 0.000 claims 8
- 230000000813 microbial effect Effects 0.000 claims 7
- 241000894006 Bacteria Species 0.000 claims 6
- 102100037886 Regenerating islet-derived protein 3-gamma Human genes 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 241000588724 Escherichia coli Species 0.000 claims 4
- 101001096072 Homo sapiens Regenerating islet-derived protein 3-gamma Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 230000029663 wound healing Effects 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 108090001090 Lectins Proteins 0.000 claims 2
- 102000004856 Lectins Human genes 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 101710086144 Regenerating islet-derived protein 3-gamma Proteins 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000000369 enteropathogenic effect Effects 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 230000000968 intestinal effect Effects 0.000 claims 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 claims 2
- 239000002523 lectin Substances 0.000 claims 2
- 210000000110 microvilli Anatomy 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 241001646719 Escherichia coli O157:H7 Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000001464 adherent effect Effects 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 230000008033 biological extinction Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 210000005026 intestinal epithelial barrier Anatomy 0.000 claims 1
- 210000004347 intestinal mucosa Anatomy 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98617007P | 2007-11-07 | 2007-11-07 | |
| US60/986,170 | 2007-11-07 | ||
| US1362007P | 2007-12-13 | 2007-12-13 | |
| US61/013,620 | 2007-12-13 | ||
| US1562007P | 2007-12-20 | 2007-12-20 | |
| US61/015,620 | 2007-12-20 | ||
| PCT/US2008/082890 WO2009062102A2 (en) | 2007-11-07 | 2008-11-07 | Compositions and methods for treatment of microbial disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014200490A Division JP6266486B2 (ja) | 2007-11-07 | 2014-09-30 | 微生物障害の処置のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011503102A JP2011503102A (ja) | 2011-01-27 |
| JP2011503102A5 true JP2011503102A5 (enExample) | 2012-12-06 |
| JP5985150B2 JP5985150B2 (ja) | 2016-09-06 |
Family
ID=40551983
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010533299A Active JP5985150B2 (ja) | 2007-11-07 | 2008-11-07 | 微生物障害の処置のための組成物および方法 |
| JP2014200490A Expired - Fee Related JP6266486B2 (ja) | 2007-11-07 | 2014-09-30 | 微生物障害の処置のための組成物および方法 |
| JP2016045739A Pending JP2016117760A (ja) | 2007-11-07 | 2016-03-09 | 微生物障害の処置のための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014200490A Expired - Fee Related JP6266486B2 (ja) | 2007-11-07 | 2014-09-30 | 微生物障害の処置のための組成物および方法 |
| JP2016045739A Pending JP2016117760A (ja) | 2007-11-07 | 2016-03-09 | 微生物障害の処置のための組成物および方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US20090202475A1 (enExample) |
| EP (3) | EP2217263A2 (enExample) |
| JP (3) | JP5985150B2 (enExample) |
| KR (2) | KR20160129099A (enExample) |
| CN (5) | CN101951945A (enExample) |
| AU (1) | AU2008323770B2 (enExample) |
| CA (1) | CA2705007A1 (enExample) |
| CO (1) | CO6280406A2 (enExample) |
| DK (1) | DK2514436T3 (enExample) |
| ES (1) | ES2662845T3 (enExample) |
| HK (2) | HK1214137A1 (enExample) |
| HR (1) | HRP20180445T1 (enExample) |
| HU (1) | HUE038588T2 (enExample) |
| IL (2) | IL205623A0 (enExample) |
| LT (1) | LT2514436T (enExample) |
| MX (2) | MX373155B (enExample) |
| NO (1) | NO2514436T3 (enExample) |
| PH (1) | PH12013501074A1 (enExample) |
| PL (1) | PL2514436T3 (enExample) |
| PT (1) | PT2514436T (enExample) |
| RS (1) | RS57021B1 (enExample) |
| RU (1) | RU2503460C2 (enExample) |
| SG (2) | SG10202007210RA (enExample) |
| SI (1) | SI2514436T1 (enExample) |
| WO (1) | WO2009062102A2 (enExample) |
| ZA (1) | ZA201003113B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101361968B (zh) | 2007-08-06 | 2011-08-03 | 健能隆医药技术（上海）有限公司 | 白介素-22在治疗脂肪肝中的应用 |
| CA2741566A1 (en) * | 2008-11-03 | 2010-06-03 | Schering Corporation | Inflammatory bowel disease biomarkers and related methods of treatment |
| US20120276149A1 (en) * | 2009-10-15 | 2012-11-01 | Dan Littman | Methods for modulating bacterial infection |
| US20130130965A1 (en) * | 2010-04-08 | 2013-05-23 | University Of Virginia Patent Foundation | Method to detect and treat infectious or inflammatory diarrhea based on reg1 |
| CN102260343A (zh) | 2010-05-25 | 2011-11-30 | 健能隆医药技术（上海）有限公司 | 重组人g-csf二聚体在治疗神经损伤疾病中的用途 |
| CN102380091A (zh) | 2010-08-31 | 2012-03-21 | 健能隆医药技术（上海）有限公司 | 白介素-22在治疗病毒性肝炎中的应用 |
| US9642917B2 (en) | 2011-07-25 | 2017-05-09 | Generon (Shanghai) Corporation, Ltd. | Use of G-CSF dimer in preparation of medicament for treatment of neurodegenerative diseases |
| JP2015500482A (ja) * | 2011-12-05 | 2015-01-05 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | グラフェン−生体分子バイオ電子デバイス |
| CN102559759A (zh) * | 2011-12-19 | 2012-07-11 | 西安交通大学医学院第一附属医院 | Hip/pap重组腺病毒及其抗溃疡性结肠炎的应用 |
| CN103182072B (zh) | 2011-12-27 | 2017-05-03 | 健能隆医药技术（上海）有限公司 | 白介素‑22在治疗和预防神经损伤疾病或神经退行性疾病中的用途 |
| KR101431324B1 (ko) * | 2012-08-20 | 2014-08-20 | 성균관대학교산학협력단 | ＷＫＹＭＶｍ 펩티드를 포함하는 염증성 장질환 예방 또는 치료용 약학적 조성물 |
| US9314504B2 (en) * | 2013-03-14 | 2016-04-19 | Taipei Medical University | Use of members of IL-10 cytokine family |
| WO2014139182A1 (en) | 2013-03-15 | 2014-09-18 | Shenzhen Hightide Biopharmaceutical, Ltd. | Compositions and methods of using islet neogenesis peptides and analogs thereof |
| LT2970422T (lt) | 2013-03-15 | 2018-06-25 | F. Hoffmann-La Roche Ag | Il-22 polipeptidai ir il-22 su fc sulieti baltymai bei panaudojimo būdai |
| US10646548B2 (en) * | 2013-10-08 | 2020-05-12 | Georgia State University Research Foundation, Inc. | Compositions including IL-18 and IL-22 and their use in anti-viral therapies |
| CN103554267A (zh) * | 2013-10-15 | 2014-02-05 | 山西农业大学 | 一种具有抗菌功能的融合蛋白及其构建方法和应用 |
| JP5515104B1 (ja) * | 2013-10-25 | 2014-06-11 | 独立行政法人農業・食品産業技術総合研究機構 | 抗酸菌の増殖促進剤、これを添加して培養する抗酸菌の培養方法、及び、これを含有する抗酸菌の培養用培地 |
| CN112386680B (zh) | 2013-11-07 | 2024-05-24 | 纪念斯隆-凯特林癌病中心 | 在胃肠道移植物抗宿主病的治疗中使用il-22的方法 |
| CN104623637A (zh) | 2013-11-07 | 2015-05-20 | 健能隆医药技术（上海）有限公司 | Il-22二聚体在制备静脉注射药物中的应用 |
| CN109206484B (zh) * | 2015-11-20 | 2021-06-18 | 深圳市南山区人民医院 | 一种用于预防和治疗肠致病大肠杆菌感染的肽段 |
| WO2017181143A1 (en) | 2016-04-15 | 2017-10-19 | Generon (Shanghai) Corporation, Ltd. | Use of il-22 in treating necrotizing enterocolitis |
| CA3024917A1 (en) * | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Combinations of mrnas encoding immune modulating polypeptides and uses thereof |
| CN117986343A (zh) * | 2017-07-13 | 2024-05-07 | 健康老龄化公司 | 用于保护氧敏感革兰氏阳性菌的REG3α |
| JP2020533301A (ja) | 2017-09-06 | 2020-11-19 | イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ | インターロイキン−１８バリアントとその利用法 |
| WO2020064702A1 (en) * | 2018-09-25 | 2020-04-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma |
| US12029778B2 (en) | 2019-05-13 | 2024-07-09 | Yale University | Interleukin-18 mimics and methods of use |
| US20240150453A1 (en) | 2021-03-09 | 2024-05-09 | Massachusetts Institute Of Technology | Methods of predicting response to anti-tnf blockade in inflammatory bowel disease |
| CN113304247B (zh) * | 2021-04-01 | 2024-03-19 | 上海市儿科医学研究所 | Reg4蛋白及其在抵抗肠炎伤寒沙门氏菌感染中的应用 |
| CN114409758A (zh) * | 2022-01-24 | 2022-04-29 | 上海市儿科医学研究所 | Reg4抗菌肽治疗致病性大肠埃希菌感染的应用 |
| CN114344451B (zh) * | 2022-01-25 | 2023-09-26 | 上海市肺科医院 | Reg4抗菌肽治疗铜绿假单胞菌感染性肺炎的应用 |
| WO2025106551A1 (en) * | 2023-11-14 | 2025-05-22 | Rowan University | Hydrogel compositions comprising synergistic antimicrobial peptides (amps) and methods of making same |
Family Cites Families (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| WO1984003506A1 (en) | 1983-03-08 | 1984-09-13 | Commw Serum Lab Commission | Antigenically active amino acid sequences |
| EP0138854B1 (en) | 1983-03-08 | 1992-11-04 | Chiron Mimotopes Pty. Ltd. | Antigenically active amino acid sequences |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US5683688A (en) | 1984-05-31 | 1997-11-04 | Genentech, Inc. | Unglycosylated recombinant human lymphotoxin polypeptides and compositions |
| NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5571689A (en) | 1988-06-16 | 1996-11-05 | Washington University | Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid |
| US5663143A (en) | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5750373A (en) | 1990-12-03 | 1998-05-12 | Genentech, Inc. | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants |
| ATE102631T1 (de) | 1988-11-11 | 1994-03-15 | Medical Res Council | Klonierung von immunglobulin sequenzen aus den variabelen domaenen. |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| AU641673B2 (en) | 1989-06-29 | 1993-09-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| WO1991006629A1 (en) | 1989-10-24 | 1991-05-16 | Gilead Sciences, Inc. | Oligonucleotide analogs with novel linkages |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| ES2157889T3 (es) | 1990-06-27 | 2001-09-01 | Biogen Inc | Linfotoxina complejada de superficie. |
| DE69132709T2 (de) | 1990-06-29 | 2002-06-20 | Large Scale Biology Corp., Vacaville | Melaninproduktion durch transformierte mikroorganismen |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
| US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
| DE69130831T2 (de) | 1990-11-21 | 1999-09-16 | Iterex Pharmaceuticals Ltd. Partnership, San Diego | Synthese äquimolarer mischungen vielzähliger oligomere, speziell oligopeptidmischungen |
| US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Ｈｉｖ感染治療のための異種複合抗体 |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| ATE295420T1 (de) | 1992-02-06 | 2005-05-15 | Chiron Corp | Marker für krebs und biosynthetisches bindeprotein dafür |
| WO1994004690A1 (en) | 1992-08-17 | 1994-03-03 | Genentech, Inc. | Bispecific immunoadhesins |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
| US5639635A (en) | 1994-11-03 | 1997-06-17 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| AU5632296A (en) | 1995-04-27 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6027888A (en) | 1996-04-05 | 2000-02-22 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells |
| EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
| ATE296315T1 (de) | 1997-06-24 | 2005-06-15 | Genentech Inc | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
| AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| IL138608A0 (en) | 1998-04-02 | 2001-10-31 | Genentech Inc | Antibody variants and fragments thereof |
| PT1071700E (pt) | 1998-04-20 | 2010-04-23 | Glycart Biotechnology Ag | Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| EP1082433A4 (en) * | 1998-05-29 | 2003-01-02 | Human Genome Sciences Inc | Interleukins 21 and 22 |
| US20010023070A1 (en) * | 1998-05-29 | 2001-09-20 | Reinhard Ebner | Interleukins-21 and 22 |
| US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
| JP2002533726A (ja) | 1998-12-28 | 2002-10-08 | サネシス ファーマシューティカルス インコーポレイテッド | 結合のための小有機分子リガンドの同定 |
| PL220113B1 (pl) | 1999-01-15 | 2015-08-31 | Genentech Inc | Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc |
| EP2278003B2 (en) | 1999-04-09 | 2020-08-05 | Kyowa Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US6939545B2 (en) * | 1999-04-28 | 2005-09-06 | Genetics Institute, Llc | Composition and method for treating inflammatory disorders |
| AU7950400A (en) | 1999-10-19 | 2001-04-30 | Kyowa Hakko Kogyo Co. Ltd. | Process for producing polypeptide |
| US20030170823A1 (en) * | 1999-12-23 | 2003-09-11 | Presnell Scott R. | Novel cytokine ZCYTO18 |
| GB0024442D0 (en) * | 2000-10-05 | 2000-11-22 | Isis Innovation | Genetic factors affecting the outcome of viral infections |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| HUP0700103A3 (en) | 2001-08-03 | 2012-09-28 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| JP2005532253A (ja) | 2001-10-25 | 2005-10-27 | ジェネンテック・インコーポレーテッド | 糖タンパク質組成物 |
| FR2833011B1 (fr) * | 2001-12-04 | 2004-10-29 | Univ Claude Bernard Lyon | Nouvelle proteine a activite inhibitrice de l'il-6 |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PRODUCING ANTIBODY COMPOSITION |
| AU2003236018A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
| KR20050000380A (ko) | 2002-04-09 | 2005-01-03 | 교와 핫꼬 고교 가부시끼가이샤 | 게놈이 개변된 세포 |
| JPWO2003084569A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物含有医薬 |
| AU2003236019A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism |
| ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| AU2003234706A1 (en) | 2002-04-15 | 2003-11-03 | Human Genome Sciences, Inc. | Antibodies that specifically bind to tl5 |
| CA2490280A1 (en) * | 2002-07-01 | 2004-01-08 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP1944320A1 (en) | 2002-12-16 | 2008-07-16 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| AU2003301059A1 (en) * | 2002-12-18 | 2004-07-22 | Wyeth | Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof |
| GB2401040A (en) * | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| ATE490275T1 (de) * | 2003-06-23 | 2010-12-15 | Genetics Inst Llc | Antikörper gegen interleukin-22 und verwendungen dafür |
| JP4734245B2 (ja) * | 2003-08-01 | 2011-07-27 | ストラタテック コーポレーション | 外因性ポリペプチドを発現するヒト皮膚等価物 |
| JPWO2005035586A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
| JPWO2005035778A1 (ja) | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法 |
| ME01775B (me) | 2003-11-05 | 2011-02-28 | Glycart Biotechnology Ag | Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom |
| JPWO2005053742A1 (ja) | 2003-12-04 | 2007-06-28 | 協和醗酵工業株式会社 | 抗体組成物を含有する医薬 |
| US20050277593A1 (en) * | 2004-05-24 | 2005-12-15 | Washington University | Therapeutic uses of Reg protein |
| RU2302460C1 (ru) * | 2005-11-02 | 2007-07-10 | Институт цитологии и генетики Сибирского отделения Российской академии наук (СО РАН) | РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pBi101-IL18, КОДИРУЮЩАЯ СИНТЕЗ ИНТЕРЛЕЙКИНА-18 ЧЕЛОВЕКА В ТРАНСГЕННЫХ РАСТЕНИЯХ |
| JP2009541338A (ja) * | 2006-06-19 | 2009-11-26 | ワイス | Ｉｌ−２２およびｉｌ−１７の調節方法 |
-
2008
- 2008-11-07 KR KR1020167030030A patent/KR20160129099A/ko not_active Ceased
- 2008-11-07 WO PCT/US2008/082890 patent/WO2009062102A2/en not_active Ceased
- 2008-11-07 JP JP2010533299A patent/JP5985150B2/ja active Active
- 2008-11-07 EP EP08848478A patent/EP2217263A2/en not_active Withdrawn
- 2008-11-07 SI SI200831926T patent/SI2514436T1/en unknown
- 2008-11-07 PT PT121695720T patent/PT2514436T/pt unknown
- 2008-11-07 DK DK12169572.0T patent/DK2514436T3/en active
- 2008-11-07 MX MX2015008367A patent/MX373155B/es unknown
- 2008-11-07 EP EP12169572.0A patent/EP2514436B1/en active Active
- 2008-11-07 SG SG10202007210RA patent/SG10202007210RA/en unknown
- 2008-11-07 MX MX2010005108A patent/MX2010005108A/es active IP Right Grant
- 2008-11-07 AU AU2008323770A patent/AU2008323770B2/en not_active Ceased
- 2008-11-07 KR KR1020107012426A patent/KR101867606B1/ko not_active Expired - Fee Related
- 2008-11-07 CN CN2008801241737A patent/CN101951945A/zh active Pending
- 2008-11-07 RU RU2010122982/10A patent/RU2503460C2/ru active
- 2008-11-07 RS RS20180324A patent/RS57021B1/sr unknown
- 2008-11-07 EP EP17208162.2A patent/EP3360567A1/en not_active Withdrawn
- 2008-11-07 ES ES12169572.0T patent/ES2662845T3/es active Active
- 2008-11-07 HU HUE12169572A patent/HUE038588T2/hu unknown
- 2008-11-07 CA CA2705007A patent/CA2705007A1/en not_active Abandoned
- 2008-11-07 CN CN201510262894.6A patent/CN104888193A/zh active Pending
- 2008-11-07 LT LTEP12169572.0T patent/LT2514436T/lt unknown
- 2008-11-07 SG SG2012082434A patent/SG185972A1/en unknown
- 2008-11-07 US US12/291,380 patent/US20090202475A1/en not_active Abandoned
- 2008-11-07 CN CN2013100500120A patent/CN103142999A/zh active Pending
- 2008-11-07 PL PL12169572T patent/PL2514436T3/pl unknown
- 2008-11-07 CN CN201811093788.XA patent/CN108815508A/zh active Pending
- 2008-11-07 CN CN2011101151819A patent/CN102172395A/zh active Pending
- 2008-11-07 NO NO12169572A patent/NO2514436T3/no unknown
-
2010
- 2010-05-04 ZA ZA2010/03113A patent/ZA201003113B/en unknown
- 2010-05-09 IL IL205623A patent/IL205623A0/en unknown
- 2010-05-26 CO CO10063303A patent/CO6280406A2/es not_active Application Discontinuation
-
2011
- 2011-05-20 US US13/112,850 patent/US20110280828A1/en not_active Abandoned
-
2012
- 2012-08-03 US US13/566,760 patent/US20130052159A1/en not_active Abandoned
-
2013
- 2013-05-27 PH PH12013501074A patent/PH12013501074A1/en unknown
-
2014
- 2014-09-30 JP JP2014200490A patent/JP6266486B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-24 HK HK16102060.3A patent/HK1214137A1/zh unknown
- 2016-03-09 JP JP2016045739A patent/JP2016117760A/ja active Pending
-
2018
- 2018-03-15 HR HRP20180445TT patent/HRP20180445T1/hr unknown
- 2018-04-16 IL IL258730A patent/IL258730A/en unknown
-
2019
- 2019-01-29 HK HK19101602.7A patent/HK1259102A1/en unknown
-
2021
- 2021-01-29 US US17/162,924 patent/US20210338778A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011503102A5 (enExample) | ||
| RU2010122982A (ru) | Композиции и способы лечения микробных нарушений | |
| Barber et al. | Urinary tract infections: current and emerging management strategies | |
| Pletzer et al. | Antibiofilm peptides: potential as broad-spectrum agents | |
| McIsaac et al. | Toll-like receptors in the host defense against Pseudomonas aeruginosa respiratory infection and cystic fibrosis | |
| Payne et al. | Activity of innate antimicrobial peptides and ivacaftor against clinical cystic fibrosis respiratory pathogens | |
| Giacomucci et al. | Flagella-dependent inhibition of biofilm formation by sub-inhibitory concentration of polymyxin B in Vibrio cholerae | |
| El-Feky et al. | Effect of ciprofloxacin and N-acetylcysteine on bacterial adherence and biofilm formation on ureteral stent surfaces | |
| HRP20200727T1 (hr) | Pripravci i metode povezane s varijantama proteina a (spa) | |
| Bliven et al. | Evolution of bacterial pathogens within the human host | |
| Porte et al. | A toll-like receptor 5 agonist improves the efficacy of antibiotics in treatment of primary and influenza virus-associated pneumococcal mouse infections | |
| Luna-Castro et al. | Effect of bovine apo-lactoferrin on the growth and virulence of Actinobacillus pleuropneumoniae | |
| Lee et al. | Low concentrations of honey reduce biofilm formation, quorum sensing, and virulence in Escherichia coli O157: H7 | |
| JP2014042533A5 (enExample) | ||
| JP2017526627A5 (enExample) | ||
| Burkovski | Corynebacterium pseudodiphtheriticum: putative probiotic, opportunistic infector, emerging pathogen | |
| Avalos-Gómez et al. | Effect of apo-lactoferrin on leukotoxin and outer membrane vesicles of Mannheimia haemolytica A2 | |
| Lee et al. | Potential antimicrobial effects of human lactoferrin against oral infection with Listeria monocytogenes in mice | |
| Iqbal et al. | Effect of Phage-Antibiotic Synergism (PAS) in increasing antibiotic inhibition of bacteria caused of foodborne diseases | |
| Edwards et al. | Putative virulence factors of Plesiomonas shigelloides | |
| JP2012504958A5 (enExample) | ||
| Lee et al. | Transcriptomic analysis for genetic mechanisms of the factors related to biofilm formation in Escherichia coli O157: H7 | |
| Velhner et al. | Resistance to tetracycline in Escherichia coli and Staphylococcus aureus: brief overview on mechanisms of resistance and epidemiology | |
| Wang et al. | Differential virulence and innate immune interactions of Type I and II fimbrial genotypes of Porphyromonas gingivalis | |
| Yang et al. | Major Outer Membrane Protein from Legionella pneumophila Inhibits Phagocytosis but Enhances Chemotaxis of RAW 264.7 Macrophages by Regulating the FOXO1/Coronin‐1 Axis |